Author

Marc Petersen‐Sylla

Observed names: M. Petersen-Sylla, Marc Petersen-Sylla

Institution: Clinical Research Services

Observed institution: Clinical Research Services

OpenAlex ID: A5011928554

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

2014 · David Schnell, Susanne Buschke, et al. · Cancer Chemotherapy and Pharmacology · 44

Pharmacokinetics of serelaxin in patients with hepatic impairment: a single‐dose, open‐label, parallel group study

2014 · Zhanna Kobalava, Svetlana Villevalde, et al. · British Journal of Clinical Pharmacology · 34

Pharmacokinetics, Tolerability, and Safety of Murepavadin, a Novel Antipseudomonal Antibiotic, in Subjects with Mild, Moderate, or Severe Renal Function Impairment

2018 · Glenn E. Dale, Atef Halabi, et al. · Antimicrobial Agents and Chemotherapy · 33

Effect of gemfibrozil and rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects

2017 · Shirin Bruderer, Marc Petersen‐Sylla, et al. · British Journal of Clinical Pharmacology · 16

Pharmacokinetics, Safety, and Tolerability of Faldaprevir in Patients with Renal Impairment

2014 · Fenglei Huang, Viktoria Moschetti, et al. · Antimicrobial Agents and Chemotherapy · 6

PP192—Pharmacokinetics of Selexipag in Subjects with Severe Renal Impairment Compared with Healthy Subjects

2013 · N. Fischer, H. Cruz, et al. · Clinical Therapeutics · 2

Effect of Gemfibrozil on The Pharmacokinetics of Selexipag, An oral Prostacyclin Receptor Agonist, And Its Active Metabolite In Healthy Male Subjects

2017 · S. Bruderer, M. Petersen-Sylla, et al. · Clinical Therapeutics

Effect of Rifampicin on The Pharmacokinetics of Selexipag, An Oral Prostacyclin Receptor Agonist, and Its Active Metabolite In Healthy Male Subjects

2017 · S. Bruderer, M. Petersen-Sylla, et al. · Clinical Therapeutics

Works count: 8

Citation count: 135

H-index: 5

I10-index: 4